Results 161 to 170 of about 67,119 (304)

First‐Line Treatment of IGHV‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens

European Journal of Haematology, EarlyView.
ABSTRACT Immunoglobulin heavy chain variable region‐unmutated (IGHV‐U) chronic lymphocytic leukemia (CLL) represents a biologically aggressive subgroup with limited responsiveness to chemoimmunotherapy (CIT). To clarify the comparative effectiveness of available frontline options, we conducted a comprehensive Bayesian network meta‐analysis of ...
Santino Caserta, Enrica Antonia Martino, Danilo Lofaro, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Fortunato Morabito, Valter Gattei, Massimo Gentile   +13 more
wiley   +1 more source

CD38 enzymatic activity regulates cytoplasmic [Ca²⁺].

(A) Schematic representation of enzymatic activities of CD38. (B) Free cytoplasmic Ca2+ ([Ca2+]c) relative concentration in CD38+ and CD38- LT-HSCs analyzed using Fluo-8AM dye, n = 7 (left), and ratiometric Indo-1 dye, n = 3 (right). (C) Free cytoplasmic
Anupam Sinha (1974100), Andreas Dahl (2696749), Tatyana Grinenko (18078786), Malte von Bonin (400911), Juan Alberto Pérez-Valencia (18078780), Sema Elif Eski (10899813), Manja Wobus (326146), Liliia Ibneeva (18078774), Susanne Reinhardt (7824746), Martin Bornhäuser (219605), Sumeet Pal Singh (10899822), Alexander Gerbaulet (558872), Iryna Kovtun (18078777), Ben Wielockx (13181916), Jaime Sancho (329189), Marc Schmitz (357415), Rebekka Wehner (357414), Frances Lund (18078783), Triantafyllos Chavakis (5816888), Luise Rupp (15167618)   +19 more
core   +1 more source

Plasmacytic markers as immunotherapeutic targets for primary CD20‐negative aggressive B‐cell lymphomas

British Journal of Haematology, EarlyView.
Frank Neumann, Claudia Schormann, Onur Cetin, Igor A. Kos, Moritz Bewarder, Eva C. Schwarz, Stefan Lohse, Stephanie Maurer, Philipp B. Staber, Joerg T. Bittenbring, Sigrun Smola, Konstantinos Christofyllakis, Markus Hoth, Lorenz Thurner   +13 more
wiley   +1 more source

Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens

European Journal of Haematology, EarlyView.
ABSTRACT Gain/amplification of chromosome arm 1q (+1q) is among the most frequent cytogenetic abnormalities (CAs) in multiple myeloma (MM), and a recognized marker of poor prognosis, now integrated into modern risk stratification systems. The advent of anti‐CD38 monoclonal antibodies, particularly daratumumab, has significantly improved outcomes ...
Emiliano Barbieri, Laura Arletti, Micol Quaresima, Elena Rivolti, Luca Braglia, Cecilia Fabiano, Adriana Maria Rita Alfano, Monia Rinaldini, Veronica Bizzarri, Chiara Cattani, Maria Marinelli, Barbara Gamberi   +11 more
wiley   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

European Journal of Haematology, EarlyView.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo, Richard J. Simpson, Emmanuel Katsanis   +2 more
wiley   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Evaluation of diagnostic potential of CD38 in rickets

Background: Rickets occurs in infants and children (aged 2 months to 3 years), compromising their skeletal development and damaging nervous, hematopoietic, immune, and other system functions.
Wei Chen, Chao You, Chao Deng, Xiaoshuo Ye, Yongjie Xia, Yibiao Zhou   +5 more
core   +1 more source

Cost‐effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma

British Journal of Haematology, EarlyView.
Sohaib Irfan, M. Abdullah Jamil, Muhammad Bilal Abid   +2 more
wiley   +1 more source

Proteolysis at the extracellular matrix interface: Molecular architects and regulators in health and disease

The FEBS Journal, EarlyView.
The extracellular matrix (ECM) is a dynamic scaffold that orchestrates tissue architecture and cellular communication. A critical but underexplored interplay between proteases and cluster of differentiation molecules (CD) governs ECM turnover and directs cell fate.
David Jurnečka, Matija Hrovatin, Bor Bokalj, Boris Turk   +3 more
wiley   +1 more source

Real‐world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high‐risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry

British Journal of Haematology, EarlyView.
Kenneth J. C. Lim, Elham Ashrafi, Cameron Wellard, Elizabeth M. Moore, Betty Gration, Bradley Augustson, Peter Mollee, Jennifer Zhang, Nicole Wong Doo, Karen Dun, Rachel Cooke, Sabine Ringkowski, Adam Bryant, Georgia McCaughan, Erica Wood, Zoe McQuilten, P. Joy Ho, Hang Quach, Andrew Spencer   +18 more
wiley   +1 more source